Acytinib is a targeted drug for the treatment of renal cell carcinoma that can only be discontinued and switched to other treatments when disease progression or intolerable side effects occur. Axitinib is a tyrosine kinase receptor inhibitory drug, including vascular endothelial growth factor receptors (VEGFR-1, 2, and 3), which are mostly associated with angiogenesis, tumor growth, and cancer progression. Therefore, this medication is indicated for adult patients with progressive renal cell carcinoma who have failed previous treatment with a tyrosine kinase receptor inhibitor or cytokine. As long as patient benefit is observed with this drug during treatment, it should be continued until discontinued if the patient develops an intolerable toxic reaction that is not supported by dose adjustments. Common adverse reactions to axitinib include diarrhea, elevated blood pressure, fatigue, loss of appetite, nausea and vomiting, constipation, and hypothyroidism. It is contraindicated for pregnant women, lactating women and those who are allergic to this drug. In summary, acitretinib should be used under professional medical supervision in antitumor therapy, and its clinical benefit can be continued until the occurrence of intolerable toxic reactions.